Lanternfold helps people understand the differences among ibogaine tablets, extracts, plant material, and related compounds. Our work focuses on clear, evidence-first context about uncertainty, safety concerns, and legal restrictions so readers can weigh information calmly and carefully.
We are an independent information resource and do not provide medical or legal advice. Read our editorial approach and principles below to understand how content is selected and reviewed.
We collect and summarize public sources with the aim of making technical material accessible without oversimplifying uncertainty. Our editorial process emphasizes primary literature, official guidance, and established registries over anecdote or marketing material. For example, when citing regulatory frameworks or pharmacology we prioritize documents issued by recognized authorities and peer-reviewed publications.
To make sourcing transparent we link inline to the original documents when possible and note the type of source (regulatory, clinical trial, preclinical study). We also cross-check claims against tertiary references such as encyclopedic summaries; authoritative overviews like those on Wikipedia are sometimes used to confirm context for editorial framing.
Lanternfold synthesizes evidence, clarifies technical terms, and highlights safety and regulatory signals. We do not provide diagnoses, treatment, or legal counsel. Our content is for readers seeking reliable context and is not a substitute for professional advice.
When a reader needs clinical or legal guidance we recommend consulting licensed professionals or official government resources such as the U.S. National Library of Medicine for medical literature and regulatory notices from NIH/NLM.
Our aims align with transparency and replicability: sources are cited inline and review notes are retained for editorial staff.
We publish explainers, comparative guides, and safety summaries that describe categories of products, regulatory status, and evidence limitations. Content is organized by topic pages, concise technical primers, and safety-focused digests. If you arrived from an external clinic or provider page, our services overview at the Services page explains how we structure deeper reviews and commissioned briefings.
Each topical page links to the core evidence and highlights outstanding questions for researchers and readers.
Our audience includes people seeking cautious, evidence-aware context about ibogaine-related topics, clinicians and researchers wanting centralized links, and policy readers looking for clear summaries of regulatory signals. If you're exploring treatment options or formal care pathways, please consult licensed professionals; Lanternfold is not a clinic or treatment provider.
Readers who need additional context sometimes follow links to clinical providers or regional services; when appropriate we link to recognized regional treatment resources rather than promoting private providers. For a perspective on clinical research standards and trial registries we sometimes reference resources such as ClinicalTrials.gov to explain trial transparency.
Lanternfold is independent, nonprofit-in-spirit editorial work: we do not operate as a clinic, medical practice, or licensed treatment center. Our mission is to make evidence and uncertainty easier to navigate. That independence guides our funding disclosures and editorial review.
For readers seeking clinical care or regulatory updates we include links to reputable clinics and informational sites only when relevant. For example, some readers compare informational summaries to clinical program descriptions such as those used by international providers; one such program overview can be found at Ibogaine Mexico Clinic's informational site.
We also cite authoritative backgrounds on substance regulation and health policy; when discussing policy signals we might reference government health portals such as the U.S. Food & Drug Administration for regulatory context to ground statements about legal frameworks.